Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73240]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis  plan  
  
 
 
 
 
 
 
 
 
 
A placebo -controlled,  double -blind, randomized, trial of  
Diclofenac Gel AMZ001 3.06%  for the treatment of  knee  
osteoarthritis  symptoms  
 
NTC03691844  
Document  Date:  05Aug2019  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73241]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis  plan  
  
Statistical analysis plan  
 
Final 3.0  
 
A placebo -controlled, double -blind, randomized trial of 
Diclofenac Gel AMZ001 3.06 % for the treatment of  knee 
osteoarthritis symptoms  
 
 
 
 
 
 
Sponsor:  Amzell BV  
Sponsor prot ocol number:  AMZ001 -[ADDRESS_73242] number:  2018 -001934 -16 
ClinicalTrials.gov number:  [STUDY_ID_REMOVED]  
Universal trial number (UTN):  Not applicable  
Investigational product name:  [CONTACT_67076]001 3.06%  
Development phase:  2/3 
Date of final SAP:  05AUG2019  
 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73243]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -[ADDRESS_73244] of abbreviations and definition  of terms  ................................ .........................  4 
1 Introduction  ................................ ................................ ................................ ........  5 
1.1 Study objectives  and endpoints  ................................ ................................ .......................  5 
1.1.1 Objectives  ................................ ................................ ................................ ...........  5 
1.1.2 Endpoints  ................................ ................................ ................................ ...........  5 
2 Study  design  ................................ ................................ ................................ ........  6 
2.1 Overview of  study  procedures  ................................ ................................ .........................  7 
2.2 Determination of  sample  size ................................ ................................ ..........................  9 
2.3 Blinding  ................................ ................................ ................................ .........................  10 
2.4 Randomization  ................................ ................................ ................................ ..............  10 
3 Analysis sets  ................................ ................................ ................................ ...... 11 
3.1 Intention -to-Treat Analysis Set (Full  analysis set)  ................................ ........................  11 
3.2 Modified Intention -to-Treat  analysis set  ................................ ................................ ....... 11 
3.3 Per-protocol  analysis set  ................................ ................................ ................................  11 
3.4 Safety  analysis set  ................................ ................................ ................................ .........  12 
4 Statistical analyses and presentation  of data  ................................ .................  12 
4.1 General  considerations  ................................ ................................ ................................ .. 12 
4.1.1 Data presentation  ................................ ................................ ..............................  12 
4.2 Efficacy  ................................ ................................ ................................ .........................  13 
4.2.1 Primary  efficacy  analysis  ................................ ................................ .................  13 
4.2.2 Secondary  efficacy  analyses  ................................ ................................ .............  14 
4.2.3 Quality of  life analyses  ................................ ................................ .....................  17 
4.3 Safety  ................................ ................................ ................................ .............................  20 
4.3.1 Adverse  events  ................................ ................................ ................................ . 20 
4.3.2 Other  safety  endpoints  ................................ ................................ ......................  21 
5 Quality control  ................................ ................................ ................................ .. 22 
6 Layout  of output  ................................ ................................ ...............................  22 
7 References  ................................ ................................ ................................ .........  22 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73245]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -[ADDRESS_73246]  
ITT Intention -to-treat 
LK Likert  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  Mixed model repeated measures  
mITT  Modified intention -to-treat 
N/A Not app licable  
NRS  Numerical rating scale  
OA Osteoarthritis  
OMERACT - 
OARSI  The Osteoarthritis Research Society International (OMERACT) Standing Committee 
for Clinical Trials Response Criteria Initiative and the Outc ome Measures in  
Rheumatology (OARSI) committee  
PGA  Patient Global Assessment  
PP Per-protocol  
PT Preferred term  
Q1 First quartile  
Q3 Third quartile  
QD Once daily  
QoL Quality of life  
Randomized  Subject randomized to study treatment  
SAE  Serious adver se event  
SAF Safety analysis set  
SAP Statistical analysis plan  
Screened  Subject who enters the screening phase of the study  
SD Standard deviation  
SDTM  Study data tabulation model  
SE Standard error  
SOC  System organ class  
TLF Tables, listings and fig ures 
VAS  Visual analog scale  
WHO  World Health Organisation  
WOMAC  Western Ontario and McMaster Universities Osteoarthritis Index  
WPAI  Work and Productivity and Activity Index  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73247]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 5 of 22  1 Introduction  
This document describes the planned statistical analyses and da ta presentations for study 
AMZ001 -006 as outlined in protocol version 1.2 dated 22NOV2018.  
 
1.1 Study objectives and  endpoints  
 
1.1.1 Objectives  
 
The primary objective of this study is:  
â€¢ To evaluate the c hange in pain intensity, in terms of the WOMAC pain score of th e target 
knee  
The secondary objectives of this study are:  
â€¢ To evaluate changes in symptoms of OA  
â€¢ To evaluate the changes in physical  functioning  
â€¢ To evaluate administration regimens of AMZ001  
â€¢ To evaluate the safety and tolerability of  AMZ001  
â€¢ To evaluate chan ges in quality of  life 
 
1.1.2 Endpoints  
 
The primary endpoint of this study (double -blind treatment groups only) is:  
â€¢ The change from baseline in WOMAC pain sub -score (questions 1 to 5) in the target knee 
as evaluated at week  4. 
 
The secondary endpoints of this study (double -blind treatment groups only) are:  
â€¢ Changes from baseline in WOMAC total score and the WOMAC functio n and stiffness 
scores at week  4 
â€¢ Changes from baseline in constant and intermittent OA pain assessed by [CONTACT_67060] P scores at 
week  4 
â€¢ Changes from baseline in WOMAC pain weight -bearing score (questions 1, 2, and 5) and 
non-weight bearing score (questions 3 and 4)  at week  4 
â€¢ Changes from baseline in physical function assessed by [CONTACT_67061] -stand test at week  4 
â€¢ OMERACT -OARSI responder rate at week  4 
â€¢ Total dose of rescue medication calculated as the sum of tablets used, based on pi[INVESTIGATOR_67056]  
â€¢ Time between baseline and first use of rescue  medication  
â€¢ Changes from baseline in WOMAC pain sub -score (questions 1 to 5) between group s 
receiving AMZ001 QD and BID in the target knee as evaluated at week  4 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73248]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 6 of 22  â€¢ Changes from baseline in constant and intermitten t OA pain assessed by [CONTACT_67062]001 QD and BID at week  4 
â€¢ Changes from baseline in WOMAC pain weight -bearing score (questions 1, 2, and 5) and 
non-weight bearing score (questions 3 and 4) between groups receiving AMZ001 QD and 
BID at week 4  
â€¢ Changes from baseline in physical function assessed by [CONTACT_67061] -stand te st between 
AMZ001 QD and BID at week  4 
â€¢ Changes from baseline in WOMAC total score and the WOMAC function and stiffness 
scores between AMZ001 QD and BID at week  4. 
â€¢ Changes from baseline in the impact of OA on daily living as assessed by [CONTACT_67063]  4 
â€¢ Changes from baseline in work productivity and activity assessed by [CONTACT_67064]  4 
â€¢ Changes from baseline in quality of life assessed by [CONTACT_20367]5D at week  4 
 
The safety endpoints of this study are:  
â€¢ Nature, incidence and severity of  AEs 
â€¢ Changes in laboratory safety parameters, vital signs, 12 -lead ECG parameters and  weight  
â€¢ Nature, incidence and severity of skin reactions on the application site  
2 Study  design  
The trial is a multi -center, double -blind, randomized, placebo -controlled trial of AMZ001 for the 
treatment  of knee osteoarthritis symptoms. The trial also includes a single -blind component, 
consisting of VoltarenÂ® 1 % gel. The purpose of the trial is to evaluate the efficacy, safety and 
tolerability of once or twice daily application of AMZ001 during a 28 -day period in subjects with 
radiographic and symptomatic knee osteoarthritis in either one or both knees.  
A total of appr oximately 440 subjects are planned to be randomized. The subjects will be 
randomized in a ratio of 3:3:3:2 with approximately 120 subjects in each of the three double - 
blinded treatment groups (AMZ001 BID, AMZ001 QD and placebo) and approximately 80 
subjec ts in the single -blinded treatment group (comparator VoltarenÂ® gel 1 %).  
The trial consists of three phases: screening, treatment, and foll ow-up, as illustrated in Table 1 . 
  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73249]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 7 of 22  2.1 Overview of study  procedures  
 
Table 1 Overview of study procedures  
 
 
 
 
 
Activity/Assessment   
 
 
Screening 
1a1  
 
 
Screening 
1b1  
 
 
Baseline 
V2 On Treatment Visits  14-Day 
Safety 
Follow -up2 
(Â± 5 days) 
V7  
 
 
V3  
 
 
V4  
 
 
V5  
 
 
V6 
Study Week  - - 0 1 2 3 4 6 
Study Day  -21 to - 5 -13 to -1 1 8 15 22 29 43 
Visit Window (days)  - - 0 +/- 2 +/- 2 +/- 2 +/- 2 +/- 5 
Informed Consent  X        
Medical history  X        
Inclusion/exclusion 
criteria  X X X      
Demographic data  X        
Physical examination  X      X  
Skin Tolerability 
Assessment    X3 X X X X  
Knee X -ray (both knees)  X        
Instructions on reporting 
pain4 X        
WOMAC Questionnaire  
5,6,7   X X5 X X X X  
ICOAP Questionnaire 6   X X X X X  
Pain Diary8   X8 X8 X8 X8 X8  
Patient Global 
Assessment    X X X X X  
WPAI    X X X  X  
EQ5D    X   X X  
Satisfaction 
questionnaire      X  X  
Chair -stand test6   X  X  X  
Selection of target knee    X      
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73250]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 8 of 22   
 
 
 
 
Activity/Assessment   
 
 
Screen ing 
1a1  
 
 
Screening 
1b1  
 
 
Baseline 
V2 On Treatment Visits  14-Day 
Safety 
Follow -up2 
(Â± 5 days) 
V7  
 
 
V3  
 
 
V4  
 
 
V5  
 
 
V6 
Study Week  - - 0 1 2 3 4 6 
Study Day  -21 to - 5 -13 to -1 1 8 15 22 29 43 
Height and weight  X      X9  
Blood pressure and 
heart rate  X  
X X X X X  
Adverse events  X10 X X X X X X X 
Concomitant medication  X X X X X X X X 
Randomization    X      
Study drug dispensation 
and weighing of kit(s)    X  
X15    
Dispensation of IMP 
â€œinstructions for useâ€ 
pamphlet     
X   
X    
Instruct ion of study drug 
application and 
frequency of use     
X      
Application of morning 
study drug on site under 
staff supervision     
X  
X  
X  
X  
X  
Weighing of kit(s) for 
compliance assessment     
X X X X  
Rescue medication 
dispense    X  (X)11 (X)11   
Resc ue medication 
collection12     (X)11 (X)11 X  
12 lead ECG  X      X  
(Rescue) Analgesic 
Wash -out  X X X X X X  
Hematology  X   X X X X  
Safety chemistry and 
urine dipstick  X   X X X X  
Pregnancy test13 X  X  X  X  
Blood sample for plasma 
level of diclo fenac 14     
X  
X  
EQ5D: EuroQol -5 Domain. ICOAP: Intermittent and Constant Osteoarthritis Pain. WOMAC: The Western Ontario 
and McMaster Universities Osteoarthritis Index. WPAI: Work Productivity Activity Index.  
1. If subject  is washed  out of analgesics  at Screening  Visit  1a, the examinations  scheduled  for screening  visits  1a 
and 1b can be performed on the same  day. 
2. Phone  call. 
3. Skin assessment to be performed prior to application of study drug at baseline  visit.  
4. Subjects will be educated on appropriate expect ations around their participation in a clinical study and  the 
importance of reliably consistently and accurately reporting their pain throughout the  study.  
5. WOMAC pain sub -score (5 questions) to be assessed on a daily basis on paper at home during first wee k of 
treatment, i.e. the period between Visit 2 and Visit  3. 
6. Assessed without analgesic medication for five half -lives of t he analgesic.  
7. WOMAC assessment of hips should only be performed at the screening  visit.  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73251]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -[ADDRESS_73252] week of treatment, i.e. between Visit 2 and Visit 3). In the 
period between other subsequent vis its, the questionnaire will be completed during the evening of the day prior to 
the next  visit.  
9. Only weight  collected.  
10. Conditions previously unknown t o the subject at the time of the screening visit will be recorded as  medical 
history. All subsequent event s will be recorded as adverse events.  
11. To be collected/dispensed if previously dispensed supply of rescue medication was depleted and  empty 
packaging r eturned to site.  
12. Collection of remaining rescue medication at Visit 6. Empty packaging of previously dispe nsed kit should  be 
returned to the site if new rescue medication is requested.  
13. Serum test at screening visit, urine dipstick at all other  visits.  
14. To be done after IMP application and questionnaire/test completion (approximately 1-2 hours after  IMP 
application). Exact time of IMP application and time of blood sampling must be  documented.  
15. Dispensation is not mandatory for subjects allocated to Voltare nÂ® gel 
 
2.2 Determination of sample  size 
 
The power is determined from expected changes in the primary endpoint of the change from 
baseline in pain as evaluated by [CONTACT_67065] -score. The power calculation is based on 
data from a 4 -week double -blind diclofen ac sodium 2 % topi[INVESTIGATOR_67057] (Wadsworth et al. 2016). In this study using the WOMAC LK (Likert) 3.1 
scale (0 -4 for each question), a decrease from baseline in WOMAC pain sub -score (5 questions) 
was recorded  in the diclofenac treatment group  of 4.5 (SD 4.5) and in the placebo group 3.6 (SD 
4.2). 
The estimated common SD of 4.4 in the LK 3.1 scale can be converted to a SD of 4.4 * 2.5 = 11 
in the NRS scale. Calculations based on a series of assumptions are show n below in Table 2. 
With the assumptions of the SD of 11 (NRS scale), 120 subjects enrolled in each of the double - 
blinded treatment arms, 10 % dropout rate, normal distribution, 5 % level of significance two - 
sided, 80 % pow er, the study will be powered to d etect a treatment difference in WOMAC pain 
sub-score between AMZ001 BID and placebo of 4.2 on the NRS scale.  
 
Table 2 Power calculations for pairwise difference in WOMAC pain sub -score between AMZ001 and 
placebo with 108 e valuable subjects per group, 5 % l evel of significance, two -sided.  
 
WOMAC pain -subscore 
difference  Common SD  Power  
3.8 9 0.87 
11 0.72 
13 0.57 
4.0 9 0.90 
11 0.76 
13 0.61 
4.2 9 0.93 
11 0.80 
13 0.66 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73253]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -[ADDRESS_73254] only performed for the primary endpoint.  
It should be noted that the current trial is not designed or powered to evaluate superiority o f 
AMZ001 compared to VoltarenÂ® gel, but th e trial will provide important information on onset and 
duration of action of AMZ001 to guide future, larger trials. Also, the trial is not powered to 
evaluate superiority of AMZ001 applied twice daily as compared to once daily, but the trial will 
provide information on efficacy, safety, and tolerability of twice daily administration as compared 
to once daily administration.  
Furthermore, the trial will be used to finalize the psychometric validation of the Pain Diar y and 
the Satisfaction Questionnaire.  
 
2.3 Blinding  
 
This is a double -blind study of AMZ001 (QD and BID regimens) versus placebo, which also 
includes a single -blind active comparator (VoltarenÂ® gel 1 %).  
Due to lack of availability of VoltarenÂ® gel 1 % in metered dose -dispensers identical to that of t he 
doub le-blinded IMP, as well as due to differences in approved daily dose application schedules, 
full masking of VoltarenÂ® gel 1 % was not considered feasible for this trial.  Instead, the 
VoltarenÂ® gel 1 % is single -blinded to conceal the brand of the p roduct.  The single -blinded 
product is labelled identically to other IMPs in the trial. All double -blinded IMPs will be 
indistinguishable in appearance of the container, the label, as well as the gel appearance, smell 
and texture. The appearance of the sing le-blinded VoltarenÂ® gel tube will be masked to fully 
cover any branding  information.  
Neither subject, investigator nor staff working on the study will be aware of treatment allocation 
to the double -blind treatment groups. The dispensation type (metered do se-dispenser vs. gel tube) 
and required frequency of application risks unblinding of the allocation of VoltarenÂ® gel for the 
subjects allocated to the single -blinded treatment groups. Due to the difference in primary 
packaging material, study staff will be  indire ctly unblinded to allocations to the VoltarenÂ® gel 
treatment group.  
As the primary efficacy data analyses will be performed on the double -blinded treatment groups, 
the risk of bias associated with single -blind ed trea tment groups is considered irrelevant to the 
main data output.  
All summaries produced before database lock will be presented using dummy treatments and this 
will be explicitly stated.  
 
2.4 Randomization  
The screening/randomization procedure will be cent rally m anaged through an electronic 
Interactive Web Responding System integrated in the eCRF.  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73255]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 11 of 22  Eligible subjects will be randomized to one of four treatment groups with an allocation ratio of 
3:3:3:2. Each of the three double -blinded treatment gr oups (AMZ0 01 BID, AMZ001 QD and 
placebo) will be randomized with approximately [ADDRESS_73256] of topi[INVESTIGATOR_67058]001 gel compared with placebo. The single - 
blinded group of the comparator of VoltarenÂ® gel 1 % w ill be randomized with approximately [ADDRESS_73257] will be classified according to the below definitions of the Intention -to-Treat (ITT), 
Modified Intention -to-Treat (mITT), Per -Protocol (PP) and Safety  (SAF) analysis sets at the Blind 
Data Review Meeting before breaking the blind. The decisions will be made by [CONTACT_67066].  
Outputs on demographics and baseline characteristics, medical history, prior medicat ion and 
concomitant medication will be performed using the ITT, mITT, PP and SAF analysis sets. 
Subject disposition will be summarized for all screened subjects and protocol deviations will be 
summarized for the ITT analysis set. Exposure and compliance wi ll be performed using the ITT 
and SAF analysis sets.  
 
3.1 Intention -to-Treat Analysis Set (Full analysis  set) 
 
The ITT analysis set will include all subjects randomly allocated to a treatment, based on the 
intention to treat â€œas randomizedâ€ principle (i.e. the pla nned regimen rather than the actual 
treatment given in case of any difference).  
 
3.[ADDRESS_73258] been treated 
according to the trial protocol and fulfil the following criteria:  
 
â€¢ Abse nce of major  clinical  trial protocol  deviations  with respect  to factors  likely  to affect  the 
efficacy of the treatment, where the nat ure of such clinical trial deviations will be defined 
before breaking the blind. Major protocol violations could include al though not limited to 
major deviations of inclusion/exclusion criteria and use of prohibited  medication.  
 
â€¢ Adequate  compliance  with trial medication;  defined  as overall  compliance  of the target  knee 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73259]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 12 of 22  between 75% and  125%.  
 
The PP analysis set will be used to perform sensitivity analyses for the primary endpoint.  
 
3.[ADDRESS_73260] of treatment misallocations for review. For subjects misallocated treatment, the actual 
treatment received will be decided based on below categ ories and documented. For subjects 
receiving treatment as per the randomization, actual treatment is identical to planned treatment.  
Since dispensation of IMP occurs at  multiple timepoints (Visit 2, Visit 4 and as needed), subjects 
will fall into one of the following three actual treatment categories:  
1. IMP is dispensed correctly on all  occasions.  
2. IMP is consistentl y dispensed incorrectly on all occasions i.e. the subject received the 
same (incorrect) treatment throughout the study and the IMP received corresponds to one 
of the study treatment  groups.  
3. IMP is dispensed incorrectly on one or more occasions and the subj ect did not consistently 
receive IMP corresponding to one of the study treatment  groups.  
In order not to bias the safety reporting of the study treatment groups, any subjects falling into 
category 3 above will be included in the SAF under a separate treatm ent group â€˜AMZ â€“ 
misallocationsâ€™ and will therefore not be included in the safety summaries for any of the study 
treatment groups.  
The SAF will be used for all safety and tolerability summar ies. 
4 Statistical analyses and presentation of  data  
4.1 General consid erations  
 
Descriptive summaries and analyses when applicable will be presented for the following treatment 
groups: AMZ001 BID, AMZ001 QD, Placebo and Voltaren 1%.  
 
4.1.[ADDRESS_73261] at a 5% si gnificance level. Results 
from analyses will be presented with estimates, 95% confidence intervals (CIs) and p -values.  
Numerical data will be presented in summary tables by [CONTACT_67067] (n), the number of 
missing values (missing), arithmetic mean , standard deviation (SD), median, first and third 
quartiles (Q1, Q3), minimum (min) and maximum (max) values. The mean, median, Q1 and Q3 
will be reported to one decimal pl ace more than the raw data, the standard deviation to two 
decimal places more than the raw data and the minimum and maximum values to the same 
precision as the raw data. The summary statistics presented for categorical data will be the 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73262]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 13 of 22  number of observatio ns (n), the number of missing values (missing) and the count and percentage 
of subj ects in each category. Number of events will also be reported where  applicable.  
All data will be listed by [CONTACT_1570], subject and time point (if applicable). Age and sex will 
be displayed in all listings.  
 
4.2 Efficacy  
 
4.2.1 Primary efficacy  analysis  
 
The primary efficacy analysis will include data from the double -blind treatment groups only.  
 
[IP_ADDRESS] Derivatio n of primary e ndpoint  
 
The primary endpoint is the change from baseline at week 4 in the WOMAC pain sub -score in the 
target knee.  
The WOMAC pain sub -score is derived from WOMAC Osteoarthritis Index questionnaire as the 
sum of questions 1 to 5. It takes values in the range 0 -50, where higher values indicate greater  
pain. For c onvenience and ease of interpretation, all WOMAC scores (including the pain sub - 
score) will be normalised to a 0 -100-point scale for data analysis.  
For the primary endpoint,  
 
normalised WOMAC  pain sub -score = (WOMAC pain sub -score/50) * 100  
The full WOMAC questionnaire is assessed for the target knee at baseline (Visit 2), week 1 (Visit  
3) week 2 (Visit 4), week 3 (Visit 5) and week  4 (Visit 6).  
 
[IP_ADDRESS] Summary presentations and method of  analysis  
 
The absolute values and the absolute change from baseline in the WOMAC pain sub -score will be 
summarized over time by [CONTACT_1570].  
The primary analys is will use a r estricted maximum likelihood based repeated measures mixed 
model (MMRM) on the dependent variable absolute change from baseline of the WOMAC pain 
sub-score. The analysis will include covariates of baseline value (WOMAC pain sub -score), 
treatment, timepoint , sex, country, the subject characteristic of unilateral/bilateral knee OA at 
baseline (defined by [CONTACT_67068]) 
and treatment -by-timepoint interaction. An AR(1) covariance structu re will be used  to model the 
correlations between within -subject repeated measurements. The Kenward -Roger approximation 
will be used to estimate denominator degrees of freedom and adjust standard errors.  
Sample SAS code to be used for the MMRM analysis:  
proc mixed data= <input data> ; 
class treatment visit sex status subject ; 
model response = treatment visit treatment *visit sex country status baseline / ddfm=kr s; 
repeated visit / subject= subject type=ar1;  
lsmeans visit*treatment / diffs cl obsmargins; 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73263]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 14 of 22  run; 
where response is the change from baseline in WOMAC pain sub -score and baseline is the 
WOMAC pain sub -score at baseline, status is the categorical variable of either unilateral or 
bilateral knee OA at baseline and visit is the study timepoint.  
Least square mean estimates of change from baseline in WOMAC pain sub -score along with 95% 
confidence intervals (CI) will be presented at each time -point for each treatment group.  
Estimated treatment differences at week 4 between all treatment groups along  with associa ted 
95% confidence intervals and p -values will be presented. P -values will be interpreted according 
to the hierarchical step -down testing procedure specified for the primary objective and also with 
consideration as to whether they are secondar y or explorat ory objectives . Model -estimated least 
square means and associated 95% CI of change from baseline in WOMAC pain sub -score will 
be plotted over time by [CONTACT_1570].  
The p rimary efficacy analysis will be based on the mITT. The robustness of the results of the 
primary analysis will be investigated by a sensitivity analysis based on the PP.  
Further investigation of the robustness of the primary results (in particular, the inf luence of time 
and covariates)  may be performed, if deemed necessary.  
 
4.2.2 Secondary efficacy  analyses  
 
The secondary efficacy analyses will include data from the double -blind treatment groups only.  
[IP_ADDRESS]  Seconda ry endpoints  
 
WOMAC Osteoarthritis Index  
The WOMAC Osteoarthritis Index consists of 24 questions about aspects of the target knee over 
the previous 24 hours. The questions are split into three sections: Pain , Stiffness and Difficulty 
Performing Daily Activ ities (i.e. Physical Function ). Each question is scored on a [ADDRESS_73264] ionnaire:  
 
WOMAC scores  Range (min â€“ max)  Derivation  
Total score  0 - 240 Q1 + Q2 +â€¦.. + Q23 + Q24  
Pain sub -score  0 - 50 Q1 + Q2 + Q3 + Q4 + Q5  
Pain weight bearing sub -score  0 - 30 Q1 + Q2 + Q5  
Pain non -weight bearing sub -score  0 - 20 Q3 + Q4  
Stiffness  sub-score  0 - 20 Q6 + Q7  
Function sub -score  0 - 170 Q8 + Q9 +â€¦.. + Q23 + Q24  
 
For convenience and ease of interpret ation, all WOMAC derived scores will be normalised to a 0 - 
100-point scale for da ta analysis where, for each score  
 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73265]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 15 of 22  normalised score = (score/max possible value) * 100  
 
The full WOMAC questionnaire is assessed for the target knee at baseline (Visit 2), wee k 1 (Visit  
3) and weeks 2, 3 and 4.  
 
The WOMAC pain sub -scale is also completed at screening for both the left/right hips and the 
left/right knees. This is for the assessment of baseline status and eligib ility, the determination of 
the target knee and whether the subject has bilateral or un ilateral knee OA.  
 
Patient Global Assessment (PGA) questionnaire  
The PGA consists of a single question asking how a patientâ€™s knee OA has affected their health 
during th e last 48 hours. It is scored on an 11 -point numerical rating scale from 0 to 10, where  
higher scores represent a higher level of disease activity or worse health.  
 
The PGA is assessed at baseline and weeks 1, 2, 3 and 4.  
 
Intermittent and Constant OA Pain (ICOAP)  
The ICOAP consists of 11 items (questions) assessing pain in the target knee over the previous 
week. Each question is scored on a 5 -point scale as follows, where higher scores indicate more 
severe  pain:  
0 = no pain 
1 = mildly  
2 = moderately  
3 = severely  
4 = extremely  
The following scores are derived from answers to the ICOAP questi onnaire:  
 
ICOAP scores  Range  Derivation  
Total  0 - 44 Q1 + Q2 +â€¦.. + Q10 + Q11  
Constant pain  0 - 20 Q1 + Q2 + Q3 + Q4 + Q5  
Intermittent pain  0 - 24 Q6 + Q7 + Q8 + Q9 + Q10 + Q11  
 
All ICOAP scores will be normalised to a score out of 100 using the formulae:  
Normalized total pain score = (total pain score/44) * 100 
Normalized constant pain sub -score = (constant pain sub -score/20) *100  
Normalized inter mittent pain sub -score = (intermittent pain sub -score/24) *[ADDRESS_73266] can stand up and then sit down again in 30 
seconds without us ing their arms. Higher numbers correspond to greater physical function.  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73267]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -[ADDRESS_73268] is performed at b aseline, week 2 and week 4.  
 
Rescue Medication (paracetamol/acetaminophen)  
The total dose of rescue medication (g) taken will be determined as  
ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  # ğ‘œğ‘“ ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘œğ‘“ ğ‘Ÿğ‘’ğ‘ ğ‘ğ‘¢ğ‘’  ğ‘šğ‘’ğ‘‘ğ‘–ğ‘ğ‘ğ‘¡ğ‘–ğ‘œğ‘›  ğ‘¢ğ‘ ğ‘’ğ‘‘  Ã— 0.5  
where,  
ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  # ğ‘œğ‘“ ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘¢ğ‘ ğ‘’ğ‘‘  = (#ğ‘œğ‘“ ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘¢ğ‘ ğ‘’ğ‘‘  ğ‘ğ‘’ğ‘¡ğ‘¤ğ‘’ğ‘’ğ‘›  ğ‘‰2 & ğ‘‰4) + (#ğ‘œğ‘“ ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘¢ğ‘ ğ‘’ğ‘‘  ğ‘ğ‘’ğ‘¡ğ‘¤ğ‘’ğ‘’ğ‘›  ğ‘‰4 & ğ‘‰6) 
and 
# ğ‘œğ‘“ ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘¢ğ‘ ğ‘’ğ‘‘  ğ‘ğ‘’ğ‘¡ğ‘¤ğ‘’ğ‘’ğ‘›  ğ‘‰ğ‘– ğ‘ğ‘›ğ‘‘  ğ‘‰ğ‘— = (# ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘‘ğ‘–ğ‘ ğ‘ğ‘’ğ‘›ğ‘ ğ‘’ğ‘‘  ğ‘ğ‘¡ ğ‘‰ğ‘–) âˆ’ (# ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘Ÿğ‘’ğ‘¡ğ‘¢ğ‘Ÿğ‘›ğ‘’ğ‘‘  ğ‘ğ‘¡ ğ‘‰ğ‘—) âˆ’ 
(# ğ‘¡ğ‘ğ‘ğ‘™ğ‘’ğ‘¡ğ‘   ğ‘¢ğ‘›ğ‘ğ‘ğ‘ğ‘œğ‘¢ğ‘›ğ‘¡ğ‘’ğ‘‘  ğ‘“ğ‘œğ‘Ÿ ğ‘ğ‘¡ ğ‘‰ğ‘—) 
 
The average dose of rescue medi cation per day while on study drug (g/day) will be determined as  
 
ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  ğ‘‘ğ‘œğ‘ ğ‘’  ğ‘œğ‘“ ğ‘Ÿğ‘’ğ‘ ğ‘ğ‘¢ğ‘’  ğ‘šğ‘’ğ‘‘ğ‘–ğ‘ğ‘ğ‘¡ğ‘–ğ‘œğ‘›  ğ‘¢ğ‘ ğ‘’ğ‘‘  (ğ‘”) 
 
 
ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘‘ğ‘ğ‘¦ğ‘   ğ‘œğ‘› ğ‘ ğ‘¡ğ‘¢ğ‘‘ğ‘¦  ğ‘‘ğ‘Ÿğ‘¢ğ‘”  
where, 
 
ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘‘ğ‘ğ‘¦ğ‘  ğ‘œğ‘› ğ‘ ğ‘¡ğ‘¢ğ‘‘ğ‘¦  ğ‘‘ğ‘Ÿğ‘¢ğ‘”   =  {    ğ‘‘ğ‘¢ğ‘Ÿğ‘ğ‘¡ğ‘–ğ‘œğ‘›  ğ‘œğ‘“ ğ‘’ğ‘¥ğ‘ğ‘œğ‘ ğ‘¢ğ‘Ÿğ‘’ , ğ‘–ğ‘“ ğ‘¡ğ‘Ÿğ‘¡ ğ‘’ğ‘›ğ‘‘ ğ‘‘ğ‘ğ‘¡ğ‘’  < ğ‘‰6 ğ‘ğ‘ğ‘ğ‘œğ‘¢ğ‘›ğ‘¡  ğ‘‘ğ‘ğ‘¡ğ‘’  
ğ‘‘ğ‘¢ğ‘Ÿğ‘ğ‘¡ğ‘–ğ‘œğ‘›  ğ‘œğ‘“ ğ‘’ğ‘¥ğ‘ğ‘œğ‘ ğ‘¢ğ‘Ÿğ‘’  âˆ’ 1, ğ‘–ğ‘“ ğ‘¡ğ‘Ÿğ‘¡ ğ‘’ğ‘›ğ‘‘ ğ‘‘ğ‘ğ‘¡ğ‘’  = ğ‘‰6 ğ‘ğ‘ğ‘ğ‘œğ‘¢ğ‘›ğ‘¡  ğ‘‘ğ‘ğ‘¡ğ‘’  
 
Note: a consist ent approach to determining â€˜number of days on study drugâ€™ is taken across 
exposure, compliance and rescue medication calculations.  
 
The time between baseline and first intake of rescue medication (days) will also be determined as  
 
Date of first intake of rescue medication â€“ treatment start date  
 
For subjects that have first intake of rescue medication on the Visit 2 (treatment start) date, the 
time to first intake of rescue medication will be set to 0.5 days.  
 
[IP_ADDRESS]  Summary presentations and methods of  analysis  
 
All summaries and statistical analysis for the secondary endpoints will be performed for the mITT 
set only.  
For the following continuous secondary endpoints, absolute values and absolute change from 
baseline will be su mmarised over time by [CONTACT_64240]. Statistical analysis and hypothesis 
testing will be conducted as for the primary efficacy analysis using a mixed effects repeated 
measures model  with da ta from double -blind tre atment groups only.  
 
â€¢ WOMAC total  score  
â€¢ WOMAC function  score  
â€¢ WOMAC stiffness  score  
â€¢ WOMAC pain weight bearing  score  
â€¢ WOMAC pain non -weight bearing  score  
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73269]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 17 of 22  â€¢ Patient Global Assessment  (PGA)  
â€¢ ICOAP total OA pain  score  
â€¢ ICOAP constant OA pain  score  
â€¢ ICOAP intermittent OA pain score  
â€¢ Chair stand test, number of  repetitions  
The number of subjects using any rescue medication (i.e. at least one tablet), the total dose of 
rescue medication (g), and the average dose of rescue medication per day on study drug (g/day) 
will be su mmarized by [CONTACT_1570]. Time to first use of resc ue medication will be  
summarised by [CONTACT_67069] 95% CI. For subjects not taking any rescue medication, the total dose of 
rescue medication will be set to [ADDRESS_73270] use of rescue medication will be 
censored at the Visit 6/EOT visit date or the last date of subject participation in the study if this 
is not available.  
 
The average dose of rescue medication per day on s tudy drug will analysed using an analysis of 
covariance model with treatment, sex, baseline target knee WOMAC pain sub -score, country and 
subject characteristic of baseline unilateral/bilateral knee OA as e xplanatory variables. Least 
square mean estimates of each dependent variable along with 95% confidence intervals (CI) will 
be presented for each treatment group. Estimated treatment differences between all treatment 
groups along with associated 95% confide nce intervals and p -values will be presented.  
 
The time between baseline and first use of rescue medication will be analysed using a Cox semi - 
parametric proportional hazards model with treatment, sex, baseline target knee WOMAC pain 
sub-score, country and  subject characteristic of baseline unilateral/bil ateral knee OA as covariates. 
The relative hazards and associated confidence intervals for all pairwise comparisons will be 
estimated from the Cox model and displayed using Kaplan -Meier curves. Frequencies and rates 
will be presented by [CONTACT_1570]. Un adjusted Kaplan Meier estimates of median â€˜survivalâ€™ 
time and 95% CI will be presented by [CONTACT_1570], as stated above.  
If the assumptions underlying any of the pre -specified analyses are not considered  appropriate for 
any of the endpoints once data is  available, then alternate analyses may be presented.  
 
4.2.3 Quality of life  analyses  
 
The quality of life analyses will include data from the double -blind treatment groups only.  
 
[IP_ADDRESS]  QoL  endpoints  
 
Work Productivity  and Activity Impairment (WPAI) Questionnaire: Gen eral Health  
The WPAI General Health questionnaire consists of six questions. Responses to the questions are 
used to derive WPAI outcomes, which are expressed as impairment percentages, with higher 
numbers i ndicating greater impairment and less productivity , i.e. worse outcomes.  
 
The WPAI questions and derived endpoints are as follows:  
 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73271]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 18 of 22  WPAI Questions:  
1 = currently employed (YES/NO)  
2 = hours missed due to health problems 
3 = hours missed other reasons  
4 = hours actually worked  
5 = degree health affected pr oductivity while working (0 -10 11 -point NRS) 
6 = degree health affected regular activities (0 -10 11 -point NRS)  
 
WPAI derived endpoints  Derivation  
Percent work time missed due to health  Q2/(Q2+Q4)  
Percent impairment while working due to health  Q5/10  
Percent overall work impairment due to health  Q2/(Q2+Q4) + [(1 -(Q2/(Q2+Q4))) x (Q5/10)]  
Percent activity impairment due to health  Q6/10  
 
Derived scores are multiplied by 100 to express them in percentages.  
 
If any of the WPAI questions required to calculate  a given WPAI outcome is missing, no data 
imputation will be performed and the WPAI outcome will be set to missing . 
 
A note -to-file issued on 04JUN19 docum ents the strategy to be followed in cases where th e 
reported total number of working hours (the sum of hours in WPAI questions 2, 3 and 4) are 
considered outside the expected normal range (0 -70 hours/week) and thus are believed to be based 
on a misundersta nding of questions 2, [ADDRESS_73272] one of the fol lowing  criteria:  
 
â€¢ Report more than 70h work week at any time during the trial  OR 
â€¢ Report more than 60h work week at any time during the trial  AND  
o Increase of more than 80% in total work hours per week from one or more 
previous visits, with a defined minimum  reference value of 25 hours per  week  
o Decrease of more than 50% in total work hours per week form one or more 
previous visits, with a defined min imum reference value of 25 hours per  week.  
 
The algorithm will be applied prior to unblinding, to ensure unbias ed analysis of the valid data 
only. The data from the WPAI questionnaire not affected by [CONTACT_67070] 
(i.e. questions 1, 5 - if applicable - and 6) will not be excluded from analysis.  
 
The WPAI is assessed at baseline and weeks 1, 2 a nd 4.  
 
EQ5D  
The EQ -5D is a standardized measure of health status that consists of 5 dimensions (mobility, 
self-care, usual activities, pain/disco mfort, anxiety/depression) each measured on 5 levels (no 
problems, slight problems, moderate problems, severe p roblems and extreme problems) and a 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73273]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 19 of 22  a) High im provement in at least 1  of the WOMAC pain or function sub -scores  
or 
b) Moderate improvement in at least [ADDRESS_73274]â€™s self -rated health. The VAS is scored from 0 -100 where 0 corresponds to 
â€˜the worst health  you can imagineâ€™ and 100 to the â€˜the best health you can imagineâ€™.  
The EQ5D is assessed at baseline, week [ADDRESS_73275] -OARSI responder criteria (Pham, et al., 2004) are based on the WOMAC pain 
and function sub -scores and the Patient Global Assessment (PGA) questionnaire.  
A subject is defined as a responder if they de monstrate either  
 
 
where high improvement is defined as  
â€¢ Relative improvement of â‰¥ 50% (i.e. relative change â‰¤ -50%) from baseline  AND  
â€¢ Absolute improvement of â‰¥ 20 (i.e. absolute change â‰¤ -20)) from baseline 
and moderate improvement is defined as  
â€¢ Relative improvement of â‰¥ 20% (i.e. relative change â‰¤ -20%)) from baseline  AND  
â€¢ Absolute improvement of â‰¥ 10 (i.e. absolute change â‰¤ -10)) from  baseline.  
and 
 
relative change = percentage change during the study  
= ((final score â€“ baselin e score)/ baseline score) * 100 
absolute change = absolute change during the study  
= final score (normalised) â€“ baseline score (normalised)  
In the situation that at least one of the three endpoints (i.e. WOMAC pain and function s ub-scores 
and PGA) required to assess the responder criteria is missing:  
â€¢ If the available endpoints satisfy the responder criteria, then the subject will be classified 
as a responder. (e.g. If a subject has high improvement on the WOMAC pain sub -score but 
the WOMAC function sub -score and PGA are missing the n the subject is a  responder).  
â€¢ If the available endpoints do not satisfy the responder criteria AND there is no possibility 
that they could have been a responder when considering possible values for the missing 
score(s), then the response will be set to no n-response. (e.g. If a subject does not achieve 
moderate response on either the WOMAC pain sub -score or the PGA and the WOMAC 
function sub -score missing then the subject is a  non-responder).  
â€¢ If the available endpoints do NOT satisfy the responder criteria BUT the subject could 
have been  a responder depending on the possible values for the missing score(s)), then the 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73276]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 20 of 22  response will be set to missing (e.g. If either of the WOMAN pain or function sub -scores 
are missing then the response rate will be set to  missing). 
 
OMERACT -OARSI responder criteria will be evaluated at weeks 1, 2, 3 and 4.  
[IP_ADDRESS] Summary presentations  and methods of an alysis  
 
Summaries and analysis will be performed for the mITT set only.  
For the following QoL endpoints, absolute values and absolute cha nge from baseline will be 
summarized over time by [CONTACT_1570]. Statistical analysis will be conducted as for the 
primary efficacy analysis using a mixed effects repeated measures model . 
â€¢ WPAI % time  missed  
â€¢ WPAI % impairment while  working  
â€¢ WPAI % overall work  impairment  
â€¢ WPAI % activity  impairment  
â€¢ EQ5D  VAS  
 
4.3 Safety  
Safety parameters will be evaluated for the sa fety analysis data set.  
 
4.3.1 Adverse  events  
 
Adverse events (AEs) will be classified according to MedDRA version 21.0.  
An AE overview summary table will be prepared including the number of subjects reporting an 
AE, the percentage of subjects (%) with an AE, an d the number of events (E) reported for t he 
following categories:  
â€¢ Treatment -emergent AEs  
â€¢ Deaths  
â€¢ Serious adverse events (SAEs)  
â€¢ AEs leading to withdrawal of study  drug 
â€¢ Severe and life -threatening  AEs 
â€¢ Adverse drug  reactions  
Treatment emergent AEs are defined as any AE that has occurred after the fir st administration of 
IMP administration.  
ADRs are defined as all untoward and unintended responses to an IMP related to any dose 
administered, i.e. all AEs which are probably or possibly related to IMP.  
Treatment -emergent AEs will be summarized in a table by [CONTACT_67071], i.e., system organ 
class (SOC) and preferred term (PT) for MedDRA. The table will display the total number of 
subjects reporting an AE, the percentage of subjects (%) with an AE and the number o f events (E) 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73277]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -006 Statistical analysis plan   
Page 21 of 22  reported. AEs will be presented by [CONTACT_67072].  
Pre-treatment AEs will be listed only.  
Summary tables will be prepared for:  
â€¢ All TEAEs  
â€¢ All non -serious  TEAEs  
â€¢ TEAEs by [CONTACT_2235]  (related/unrelated)  
â€¢ TEAEs by  [CONTACT_926]  
â€¢ TEAEs leading to  death  
â€¢ TEAEs leading to withdrawal of study  drug 
â€¢ Treatment emergent SAEs  
Data listings will be provided for:  
â€¢ All AEs sorted by [CONTACT_67073]  
â€¢ All AEs sorted by [CONTACT_67074] 
â€¢ SAEs  
â€¢ AEs leadi ng to  death  
â€¢ AEs leading to withdrawal of study  drug 
â€¢ Pre-treatment  AEs 
 
4.3.2 Other safety endpoints  
 
[IP_ADDRESS]  Laboratory  meas urements  
 
Absolute values and change from baseline in hematology and clinical biochemistry parameters 
will be summarized by [CONTACT_67075].  
Frequency and percentage for categorical urinalysis data will be presented b y visit and treatment 
group, when relevant.  
Laboratory values will be flagged if outside the reference range. 
A listing of abnormal values will be presented.  
[IP_ADDRESS]  Vital  signs and  ECG  
 
Descriptive statistics for vital signs parameters (systolic and diastolic blo od pressure, heart rate, 
and body temperature), weight and [ADDRESS_73278] as the laboratory  parameters.  
 
[IP_ADDRESS]  Skin tolerability assessment  
 
Sponsor:  Amzell BV  05AUG2019  
Version 3.[ADDRESS_73279]: AMZ001 3.06% Gel  
Study ID:  AMZ001 -[ADDRESS_73280] 20 10 (or later) files 
(DOCX) files will be used as the format for TLF collections (EOT documents).  
All outp ut will be produced using SAS version 9.4 or a later version.  
The sponsor name, protocol number, SAS program and output name [CONTACT_67077] a footnote. The header of the EOT document will include date of collection and 
status (dra ft/final).  
On an agreed timeline before the Database Release Meeting, a draft version of the EOT 
documents using dummy treatment groups will be produce d and distributed for review. An Output 
Review Meeting will be held to consolidate the review findings an d prepare a list of revision 
requests to be used for the second draft of the EOT documents. The second delivery of EOT 
documents (with dummy treatment groups) will have been subject to full  QC. 
7 References  
Measure of Intermittent and Constant Osteoarthritis Pain: ICOAP Userâ€™s Guide, Version 6: July 
7 2010.  
Pham, T., Heijde, D. v., Alt man, Anderson, Bellamy, Hochberg, . . . Dougados, W. a. (2004).  
OMERACT -OARSI Initiative: Osteoarthritis Research Society International set of 
responder criteria f or osteoarthritis clinical trials revisited. OsteoArthiritis and Cartilage , 
389-399. 
Wadsworth, L., Kent, J., & Holt, R. (2016). Efficacy and safety of diclofenac sodium 2% topi[INVESTIGATOR_67059]: a randomized, double -blind, vehicl e-controlled, 4 
week study. Current Medical Research and Opi[INVESTIGATOR_1649] , 32(2) 241 -250. 